Nephrologists Attending the American Society of Nephrology Virtual Meeting Point to New Data on the SGLT2 Inhibitor Class as Being the Most Compelling Presented at the Conference
According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during...